Economic Analyses Shows “Delinking” Policy Hands Big Pharma a Financial Windfall totaling $32 Billion Annually (Washington, D.C.) — Pharmaceutical Care Management Association (PCMA) issued the following statement on the introduction of H.R. 6283, “Delinking Revenue from Unfair Gouging Act” or
Pharmacy Benefit Companies Innovate to Provide Choice for Clients, Lower Costs for Patients Even as Congress considers more government intervention and “drug pricing” legislation that ironically may prove only to increase prescription drug costs, pharmacy benefit companies continue to evolve
U.S. Senators Peter Welch (D-VT), Mike Braun (R-IN), and Amy Klobuchar (D-MN) recently introduced legislation that will crack down on drug companies’ patent abuse, specifically patent thickets. A companion bill in the House of Representatives was introduced by U.S. Representatives Jodey
Conversation on “Improving Competition to Lower Drug Prices” Emphasizes Need to Stop Abuse of the Patent System Last week, The Hill hosted an event titled, “Prescription for Change: Improving Competition to Lower Drug Prices.” During the event, lawmakers and a panel of drug
As Congress considers anti-PBM legislation in the new year, it is important lawmakers are aware that allowing the government to dictate the winners and losers in the health care system, according to policymakers and experts, will do nothing to actually
A wide array of voices from across the country are calling on lawmakers to oppose recently reintroduced legislation, the Pharmacy Benefit Manager Transparency Act (S.127), which fundamentally misconstrues the role of pharmacy benefit companies, unfairly proposes to take away employers’
Makers of brand-name drugs called out by the Trump administration for potentially stalling generic competition have hiked their prices by double-digit percentages since 2012 and cost Medicare and Medicaid nearly $12 billion in 2016, a Kaiser Health News analysis has
Today, Thursday March 9, The Hill is hosting an important conversation titled: “Prescription for Change: Improving Competition to Lower Drug Prices,” featuring: David Schweikert (R-AZ), Member, Ways & Means Committee Tina Smith (D-MN), Member, Senate HELP Committee Lauren Aronson, Executive
Even including discounts, however, the company’s net profit margin for 2017 was 34 percent, its highest since at least 2000, when it was half that high.
PCMA said the changes wouldn’t be as disruptive as others argued, and highlighted several classes of drugs
©2024 PCMA. All Rights Reserved.
